You are here
METACLIPSE THERAPEUTICS CORP
UEI: MU6JZBDZR8X1
# of Employees: 5
HUBZone Owned: No
Socially and Economically Disadvantaged: Yes
Woman Owned: No
Award Charts
Award Listing
-
Clinical Evaluation of a Personalized Vaccine Immunotherapy in Combination with Checkpoint Inhibitors for Triple Negative Breast Cancer
Amount: $2,094,022.00PROJECT SUMMARY Triple negative breast cancer (TNBC) is an aggressive type of breast cancer with limited effective therapies. Each year more than 40,000 new cases of TNBC are diagnosed in the US alone ...
SBIRPhase II2021Department of Health and Human Services National Institutes of Health -
DEVELOPMENT OF MEMBRANE ANCHORED CYTOKINES AS NOVEL VACCINE ADJUVANTS FOR THE ELDERLY.
Amount: $2,199,976.00Interleukin-12 (IL-12) and granulocyte macrophage colony-stimulating factor (GM-CSF) are endogenous immune activators. Earlier studies using soluble IL-12 and GM-CSF as vaccine adjuvants were unsucces ...
SBIRPhase II2020Department of Health and Human Services National Institutes of Health -
Development of Membrane Anchored Cytokines as Novel Vaccine Adjuvants for the Elderly
Amount: $1,948,234.00lnterleukinILand granulocyte macrophage colony stimulating factorGM CSFare endogenous immune activatorsEarlier studies using soluble ILand GM CSF as vaccine adjuvants were unsuccessful due to toxicity ...
SBIRPhase II2019Department of Health and Human Services National Institutes of Health -
IND enabling studies for a personalized immunotherapy for triple negative breast cancer
Amount: $1,860,016.00Abstract The worldwide incidence of breast cancer ismillionTriple negative breast cancersTNBCaccount forof total breast cancer casesworldwideAnnuallyovernew cases of TNBC are diagnosed in the US alone ...
SBIRPhase II2017Department of Health and Human Services National Institutes of Health -
DEVELOPMENT OF MEMBRANE ANCHORED CYTOKINES AS NOVEL VACCINE ADJUVANTS FOR THE ELDERLY
Amount: $230,270.00The contractor will use engineered versions of IL and GM CSF as adjuvants The engineered version of IL and GM CSF include a glycosyl phosphatidylinositol GPI anchor at the carboxyl terminal ...
SBIRPhase I2017Department of Health and Human Services National Institutes of Health -
Automating Directly Observed Therapy as a Platform Technology
Amount: $144,759.00DESCRIPTION (provided by applicant): Triple negative breast cancer (TNBC), which includes tumors lacking estrogen, progesterone, and HER-2 receptor proteins, represents 15-20% of all breast cancer dia ...
SBIRPhase I2013Department of Health and Human Services National Institutes of Health
